首页> 美国卫生研究院文献>The Yale Journal of Biology and Medicine >Focus: Vaccines: Reducing Outbreaks: Using International Governmental Risk Pools to Fund Research and Development of Infectious Disease Medicines and Vaccines
【2h】

Focus: Vaccines: Reducing Outbreaks: Using International Governmental Risk Pools to Fund Research and Development of Infectious Disease Medicines and Vaccines

机译:重点:疫苗:减少疫情:利用国际政府风险池为传染病药物和疫苗的研究与开发提供资金

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The deadliest Ebola outbreak the world has ever seen is currently ravaging West Africa, despite the concerted efforts of the World Health Organization and many national governments. The current picture is troubling, but not altogether unexpected. Ebola was initially identified in 1976, and since that time, few drugs have been developed to combat it. The same is true for myriad other dangerous infectious diseases to which the world is currently susceptible. One proposal that might prevent outbreaks of this scale and magnitude from recurring would be to have the World Health Organization (WHO) and its technical partners assess which of its member states are at high risk for a disease, either directly or indirectly, and facilitate the creation of international governmental risk pools of those member states. Risk pools would offer open-indexed grant contracts to fund vaccine and drug development for a particular disease, and pharmaceutical companies could browse the index to apply for these grants. If the risk-pool states and a particular company sign a contract, a mutually agreed upon amount of the vaccine or drug would be produced at a below-market purchase price for those states. In return, the company would keep any patents or intellectual property rights for the developed vaccines or drugs. Risk-pool countries that did not use their vaccine or drug could resell that supply on secondary markets to other countries outside of the risk pool. This arrangement will increase the supply of tested drug and vaccine candidates available for combatting unexpected outbreaks of any previously discovered major infectious disease in the future.
机译:尽管世界卫生组织和许多国家政府共同努力,但世界范围内最致命的埃博拉疫情正在席卷西非。当前情况令人不安,但并非完全出乎意料。埃博拉病毒最初于1976年被发现,从那时起,很少有药物可以对抗它。世界目前易患的其他多种危险传染病也是如此。一项可能阻止再次爆发这种规模和规模的暴发的建议是,让世界卫生组织(WHO)及其技术合作伙伴直接或间接地评估其成员国中有高风险的疾病,并促进建立这些成员国的国际政府风险池。风险池将提供开放索引的赠款合同,以资助针对特定疾病的疫苗和药物开发,制药公司可以浏览索引以申请这些赠款。如果风险池州和特定公司签订了合同,则将以低于这些州市场购买价的价格生产共同商定数量的疫苗或药品。作为回报,该公司将保留已开发疫苗或药物的任何专利或知识产权。不使用疫苗或药物的风险库国家可以在二级市场上将其供应转售给风险库之外的其他国家。这种安排将增加可供测试的药物和疫苗候选物的供应,以应对未来任何先前发现的重大传染病的意外爆发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号